Ironwood and Forest plan to file linaclotide next year after positive Phase III results
This article was originally published in Scrip
Ironwood Pharmaceuticals and Forest Laboratories will file their investigational drug linaclotide in the US in the third quarter of next year, for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC), following the success of the final Phase III trial in the drug's Phase III programme for these indications.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.